The challenges integrating U=U into HIV care around the world
Rate of neural tube defects is no higher on dolutegravir
We still have no HIV cure. But we have a better strategy for finding one
Broader hepatitis C treatment not leading to more reinfections in people with HIV
Injectable PrEP is just as effective for transgender women as it is for gay men, study analysis finds
New formulations and alternative injection sites might allow self-administration of long-acting cabotegravir and rilpivirine
Early response to Ukrainian refugees enabled continuity of HIV care, but longer-term issues must be addressed as war drags on
Second-line treatment nearly nine times more expensive than first-line in upper-middle income countries
Pilot harm reduction programmes in Africa show progress, despite challenging laws and policies
